Cargando…

Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells

Non-Hodgkin lymphoma (NHL) is one of the most common hematologic malignancies among adults for which the chimeric monoclonal anti-CD20 antibody (Ab) rituximab (RTX) is used as first-line therapy. As RTX itself is not directly cytotoxic but relies on host immune effector mechanisms or chemotherapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Chengke, Deng, Zhenghao, Li, Lan, Clayton, Frederic, Chen, Alexander L., Wei, Ran, Miles, Rodney, Stephens, Deborah M., Glenn, Martha, Wang, Xiyang, Jensen, Peter E., Chen, Xinjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914323/ https://www.ncbi.nlm.nih.gov/pubmed/26859679 http://dx.doi.org/10.18632/oncotarget.7230

Ejemplares similares

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation
por: Hayashi, Kazumi, et al.
Publicado: (2016)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

Systemic anti-CD20 (rituximab) as primary treatment for symptomatic primary uveal lymphoma
por: Tiu Teo, Honeylen Maryl, et al.
Publicado: (2019)

Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression
por: Song, Lina, et al.
Publicado: (2019)

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab
por: Muylle, Kristoff, et al.
Publicado: (2015)

Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine
por: Jo, Tatsuro, et al.
Publicado: (2012)

Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
por: Abuelgasim, Khadega A., et al.
Publicado: (2021)

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases
por: Peterlin, Pierre, et al.
Publicado: (2018)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma
por: Lara, Sandra, et al.
Publicado: (2022)

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group
por: Wada, Naoki, et al.
Publicado: (2009)

Antibody-CD20-interferon-alpha fusion protein has superior in vivo activity against human B cell lymphomas compared to Rituximab, and enhanced complement-dependent cytotoxicity in vitro
por: Yamada, Reiko, et al.
Publicado: (2013)

Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies
por: Xiao, Hongmei, et al.
Publicado: (2019)

CD20(+) cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature
por: Tschetter, Amanda J., et al.
Publicado: (2020)

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster
por: Li, Huafei, et al.
Publicado: (2015)

Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma
por: Hornberger, John, et al.
Publicado: (2008)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
por: Guan, Xu-Wen, et al.
Publicado: (2020)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab
por: Chu, Te-Wei, et al.
Publicado: (2015)

Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab
por: Rasheed, Afshan Asghar, et al.
Publicado: (2018)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021)

Association of Clinical Phenotypes in Haploinsufficiency A20 (HA20) With Disrupted Domains of A20
por: Chen, Yu, et al.
Publicado: (2020)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Capillary Leak Syndrome From Rituximab Therapy of Lymphoma
por: Vedala, Krishna, et al.
Publicado: (2020)

The Role of Rituximab in Primary Central Nervous System Lymphoma
por: Bromberg, Jacoline E. C., et al.
Publicado: (2020)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
por: Claustre, Gwladys, et al.
Publicado: (2022)

Rituximab Concentration Varies in Patients With Different Lymphoma Subtypes and Correlates With Clinical Outcome
por: Liu, Shu, et al.
Publicado: (2022)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Midostaurin potentiates rituximab antitumor activity in Burkitt’s lymphoma by inducing apoptosis
por: Ge, Xiaowen, et al.
Publicado: (2018)

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy
por: VEGA, GABRIEL G., et al.
Publicado: (2015)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_71pc1r35stf189pv8kmnsc9skl